Helicobacter Pylori Diagnostics Market Global Forecast to 2026

Jul 15
18:16

2018

Rupesh D

Rupesh D

  • Share this article on Facebook
  • Share this article on Twitter
  • Share this article on Linkedin

The global Helicobacter pylori diagnostics market size was valued at US$ 437.3 million in 2017 and is expected to witness a CAGR of 7.1% over the forecast period (2018 – 2026).

mediaimage

Helicobacter is a spiral shaped gram-negative bacteria,Helicobacter Pylori Diagnostics Market Global Forecast to 2026 Articles causing chronic inflammation and infection in stomach and duodenum leading to ulceration. H. pylori is found in 50-80% of patients with gastric ulcers and in 90% of patients with duodenal ulcers. An estimated one in six individuals infected with H. pylori are expected to eventually develop peptic ulcer disease. Infected individuals experience long asymptomatic conditions with nearly 70% of individuals having minimal symptoms such as belching, bloating, nausea, vomiting, abdominal discomfort as occasional, whereas, major symptoms includes abdominal pain, peptic ulcer, bad breath etc.

Click To Continue Reading on Helicobacter Pylori Diagnostics Market

Helicobacter infection can be diagnosed by invasive that requires gastric mucosa samples, which are obtained through endoscopy and used for biopsy or non-invasive tests that requires blood or stool samples. Invasive tests include immunoassay, rapid urease test, and histology whereas non-invasive includes stool antigen assays serology tests and urea breath test.

Prevalence of helicobacter pylori is declining in developed countries, whereas its prevalence in emerging economies is increasing. For instance, according to the Faculty of Medicine of The Chinese University of Hong Kong (CUHK), 2017, around 4.4 billion people worldwide are infected with Helicobacter pylori (H. pylori). Furthermore, same source suggested that prevalence in Africa is up to 80%, which is the highest globally, while in Asia, over 50% of the population was infected with H. pylori. Moreover, according to the International Agency for Research on Cancer report 2014, in 2012, around 952,000 new gastric cancer cases occurred globally and around 734,000 gastric cancers were estimated to occur due to H. pylori infection. Such high prevalence of Helicobacter pylori in Africa and Asia is expected to fuel the regional helicobacter market growth.

The limitations associated with diagnostic tests are expected to be a major factor restraining growth of the Helicobacter pylori diagnostics market. For instance, serology-based assays have low sensitivity and specificity, as they are unable to differentiate between active infection and IgG antibodies present in case of post treatment.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1874

Key Vendors:

Thermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc., Diasorin S.P.A., Quidel Corporation, F. Hoffmann-La Roche Ltd.(Ventana Medical Systems, Inc.), Meridian Bioscience, Inc., Exalenz Bioscience Ltd., Abbott Laboratories, Cardinal Health, Inc., and Halyard Health, Inc.

Contact Us:

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Tel: +1-206-701-6702Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/